Rogier Klok - Concepedia

Author

Rogier Klok

University of Groningen ORCID

Also Known As

Klok, R. M., R. Klok, R. M. KLOK, R. M. Klok, ROGIER M. KLOK, Rogier Klok, Rogier M Klok, Rogier M. Klok

Publications

638

Citations

H-Index

Concepts

All Affiliations

University of Groningen Pfizer (Netherlands)Pfizer (United States)Pharmac Pharmacoeconomics and Health Outcomes Research Iberia (Spain)

About

Rogier Klok is an author at University of Groningen specializing in medicine, epidemiology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	257
2	Epidemiology	4	4	153
3	Public Health	2	2	32
4	Social Sciences	1	1	11
5	Family Medicine	1	1	15

Rogier Klok

Publications

443

Citations

H-Index

Page 1

	Year	Citations
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands David Strutton, Raymond Farkouh, Stephanie Earnshaw, Journal of Infection VaccinationVaccine SafetyVaccinologyPreventive MedicineVaccine Surveillance	2011	69
Rates of pneumonia among children and adults with chronic medical conditions in Germany Stephen I. Pelton, Kimberly M. Shea, Raymond Farkouh, BMC Infectious Diseases	2015	61
Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs Harald E. Vonkeman, Rogier Klok, Maarten J. Postma, Drugs & Aging Anti-inflammatory AgentsHealth EconomicsPatient SafetyGastroenterologyPharmacoeconomics	2007	58
Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden Rogier Klok, Rose‐Marie Lindkvist, Mats Ekelund, Clinical Therapeutics VaccinologyVaccine SafetyVaccinationPreventive MedicineVaccine Efficacy	2013	52
Quality of life in relation to constipation among opioid users Fernie J. A. Penning‐van Beest, Pieter van den Haak, Rogier Klok, Journal of Medical Economics	2010	41
Methylnaltrexone bromide for the treatment of opioid‐induced constipation in patients with advanced illness – a cost‐effectiveness analysis Stephanie Earnshaw, Rogier Klok, Shrividya Iyer, Alimentary Pharmacology & Therapeutics	2010	28
Drug Costs Developments after Patent Expiry of Enalapril, Fluoxetine and Ranitidine Cornelis Boersma, Rogier Klok, Jasper M Bos, Applied Health Economics and Health Policy Drug Costs DevelopmentsHealth EconomicsPharmacologyPatent ExpiryPharmacoeconomics	2005	20
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH) Vallerie V. McLaughlin, Adnan Alsumali, Rongzhe Liu, Advances in Therapy	2023	20
Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: The impact of varying the discount rate for health Robin de Vries, Rogier Klok, J. R. B. J. Brouwers, Vaccine VaccinationDiscount RatePreventive MedicineHealth EconomicsVaccine Efficacy	2008	17
Optimising Assessments of the Epidemiological Impact in the Netherlands of Paediatric Immunisation with 13-Valent Pneumococcal Conjugate Vaccine Using Dynamic Transmission Modelling Elisabetta De Cao, Alessia Melegaro, Rogier Klok, PLoS ONE VaccinationVaccine SafetyPreventive MedicinePaediatric ImmunisationEpidemiological Impact	2014	15

Page 1